diseaseId,diseaseName,specificDiseaseId,specificDiseaseName,n_gwas_studies,has_sumstats,n_variants,description
EFO_0004502,adiponectin measurement,EFO_0004502,adiponectin measurement,8,0,41,"Adiponectin measurement is a measurement of the circulating hormone adiponectin in serum. Adiponectin regulated modulates glucose regulation and fatty acid catabolism. Low circulating adiponectin concentrations (hypoadiponectinemia; <4 μg/mL) are associated with a variety of diseases, including dysmetabolism (type 2 diabetes, insulin resistance, hypertension, dyslipidemia, metabolic syndrome, hyperuricemia), atherosclerosis (coronary artery disease, stroke, peripheral artery disease), sleep apnea, non-alcoholic fatty liver disease, gastritis and gastro-esophageal reflux disease, inflammatory bowel diseases, pancreatitis, osteoporosis, and cancer (endometrial cancer, postmenopausal breast cancer, leukemia, colon cancer, gastric cancer, prostate cancer). Hyperadiponectinemia is associated with cardiac, renal and pulmonary diseases."
EFO_0004502,adiponectin measurement,EFO_0007737,BMI-adjusted adiponectin measurement,1,0,7,Adiponection measurement that has been adjusted by subjects’ body mass index by performing linear regressions for adiponectin against BMI 
EFO_1002011,adult onset asthma,EFO_1002011,adult onset asthma,7,1,336,Asthma that starts in adulthood
EFO_0001365,age-related macular degeneration,EFO_0001365,age-related macular degeneration,16,4,108,Degenerative changes in the macula lutea of the retina.
EFO_0000249,Alzheimer's disease,EFO_0000249,Alzheimer's disease,58,9,251,"A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language."
EFO_0000249,Alzheimer's disease,EFO_1001870,late-onset Alzheimers disease,4,2,14,"This is the most common form of the disease, which happens to people age 65 and older. It may or may not run in families. So far, researchers haven’t found a particular gene that causes it. No one knows for sure why some people get it and others don’t."
EFO_0003914,atherosclerosis,EFO_0003914,atherosclerosis,5,3,12,A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
EFO_0003914,atherosclerosis,EFO_0004265,peripheral arterial disease,6,2,29,"A disorder of the arteries supplying the upper and lower extremity and the visceral organs. This includes the mesenteric arteries, the renal arteries and the aorta and excludes cerebrovascular arterial disease. Patients experience cramping and pain usually in the calves and thighs while walking. The symptoms subside with rest."
EFO_0003914,atherosclerosis,EFO_0009783,carotid atherosclerosis,1,0,4,A thickening and loss of elasticity of the walls of carotid arteries that occur with formation of atherosclerotic plaques.
EFO_0003914,atherosclerosis,MONDO_0021661,coronary atherosclerosis,3,3,97,Atherosclerosis of the coronary vasculature.
EFO_0007873,cartilage thickness measurement,EFO_0007873,cartilage thickness measurement,1,0,5,"Quantification of the thickness of cartilage in a joint, most commonly the hip joint, for example using minimal joint space width (mJSW) as a proxy measure. Cartilage thickness is an indicator of joint health, which makes it a suitable biomarker for osteoarthritis."
EFO_0003884,chronic kidney disease,EFO_0000401,diabetic nephropathy,4,2,6,"Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis."
EFO_0003884,chronic kidney disease,EFO_0003884,chronic kidney disease,11,2,62,"The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION."
EFO_0003884,chronic kidney disease,EFO_0004996,type 1 diabetes nephropathy,4,0,5,Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 1 diabetes hyperglycaemia starts in the first decades of life and is usually the only recognized cause of nephropathy.
EFO_0003884,chronic kidney disease,EFO_0004997,type 2 diabetes nephropathy,5,0,19,"Diabetic nephropathy is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. In type 2 diabetes hyperglycaemia starts after the forties, usually when the kidneys have already suffered the long‐term consequences of ageing and of other recognized promoters of chronic renal injury such as arterial hypertension, obesity, dyslipidaemia, and smoking."
EFO_0000341,chronic obstructive pulmonary disease,EFO_0000341,chronic obstructive pulmonary disease,55,13,480,A group of disorders affecting the bronchi and the lung parenchyma. It is characterized by chronic and irreversible obstruction of the airflow. It includes chronic bronchitis and pulmonary emphysema.
EFO_0000341,chronic obstructive pulmonary disease,EFO_0000464,emphysema,6,4,9,"A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing."
EFO_0000341,chronic obstructive pulmonary disease,EFO_0006505,chronic bronchitis,2,2,3,"A type of chronic obstructive pulmonary disease characterized by chronic inflammation in the bronchial tree that results in edema, mucus production, obstruction, and reduced airflow to and from the lung alveoli. The most common cause is tobacco smoking. Signs and symptoms include coughing with excessive mucus production, and shortness of breath."
HP_0012532,Chronic pain,EFO_0010100,multisite chronic pain,1,0,39,A chronic pain phenotype that is defined as the number of sites on the body at which chronic pain is experienced.
HP_0012532,Chronic pain,HP_0012532,Chronic pain,,,,"Persistent pain, usually defined as pain that has lasted longer than 3 to 6 months."
EFO_0007710,cognitive decline measurement,EFO_0007710,cognitive decline measurement,2,0,16,"quantification of some aspect of cognitive decline such as the rate at which it occurs or its severity, for example in patients with dementia or Alzheimer's disease. Cognitive decline is ususally assessed using a structured-interview protocol covering a number of standardised areas."
EFO_0009267,delirium,EFO_0009267,delirium,,,,"A disorder characterized by confusion; inattentiveness; disorientation; illusions; hallucinations; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)"
EFO_0009885,frailty measurement,EFO_0009885,frailty measurement,,,,"Quantification of some aspect of frailty.  Frailty is usually described as clinical state of heightened vulnerability to poor resolution of homeostasis after a stressor event, which thereby increases the risk of adverse outcomes, including falls, delirium, disability and mortality."
EFO_0007680,gait measurement,EFO_0007680,gait measurement,2,0,72,"quantification of some aspect of a person's gait such as rhythm, variability or step length"
EFO_0000516,glaucoma,EFO_0000516,glaucoma,11,6,235,Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.
EFO_0000516,glaucoma,EFO_0004190,open-angle glaucoma,23,2,261,Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.
EFO_0000516,glaucoma,EFO_1001022,low tension glaucoma,1,0,6,A form of GLAUCOMA in which chronic optic nerve damage and loss of vision normally attributable to buildup of intraocular pressure occurs despite prevailing conditions of normal intraocular pressure.
EFO_0000516,glaucoma,EFO_1001506,primary angle closure glaucoma,2,0,16,"A type of glaucoma with optic nerve damage in an eye that has evidence of angle closure and in which there is no evidence of a secondary cause. Evidence of optic nerve damage can include s optic disc abnormalities (Vertical cup:disc ratio over the 97. 5th percentile in the normal population), visual field defects. The role of increased intraocular pressure (IOP) in glaucoma is debated, but an IOP exceeding the 99. 5th percentile of the normal population may be considered to support the diagnosis."
EFO_0006941,grip strength measurement,EFO_0006941,grip strength measurement,12,2,547,quantification of the force applied by the hand to pull on or suspend from objects
EFO_0009762,healthspan,EFO_0009762,healthspan,2,0,26,The period of a person's life during which they are generally healthy and free from serious or chronic illness.
EFO_0003777,heart disease,EFO_0000266,aortic stenosis,3,0,8,"In the same amount or manner; to the same degree; in the role, function, or capacity of."
EFO_0003777,heart disease,EFO_0000275,atrial fibrillation,22,5,566,"Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation."
EFO_0003777,heart disease,EFO_0000318,cardiomyopathy,3,3,12,"A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive."
EFO_0003777,heart disease,EFO_0000373,congestive heart failure,2,1,3,"Heart failure accompanied by EDEMA, such as swelling of the legs and ankles and congestion in the lungs."
EFO_0003777,heart disease,EFO_0000407,dilated cardiomyopathy,2,0,16,An intrinsic cardiomyopathy that results in damage to the myocardium causing the heart to pump blood inefficiently.
EFO_0003777,heart disease,EFO_0000612,myocardial infarction,13,7,227,NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
EFO_0003777,heart disease,EFO_0001645,coronary artery disease,44,4,1069,Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)
EFO_0003777,heart disease,EFO_0003144,heart failure,10,7,67,"Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction."
EFO_0003777,heart disease,EFO_0003777,heart disease,2,2,9,A disease involving the heart and/or pericardium.
EFO_0003777,heart disease,EFO_0003911,atrial flutter,4,4,138,"Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES)."
EFO_0003777,heart disease,EFO_0004269,cardiac arrhythmia,8,4,47,"Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction."
EFO_0003777,heart disease,EFO_0005137,conduction system disorder,2,2,2,A disease involving the conducting system of heart.
EFO_0003777,heart disease,EFO_0005239,aortic valve calcification,2,0,5,Calcification of the aortic valve
EFO_0003777,heart disease,EFO_0005672,acute coronary syndrome,4,0,12,Signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to myocardial infarction.
EFO_0003777,heart disease,EFO_0009275,premature cardiac contractions,1,0,1,A type of cardiac arrythmia with ventricular or atrial contractions that are initiated early by an ectopic site (outside of the sinoatrial node).
EFO_0003777,heart disease,EFO_0009276,ventricular ectopy,1,0,1,A type of cardiac arrhythmia with premature ventricular contractions or beats caused by signals originating from ectopic sites.
EFO_0003777,heart disease,EFO_0009277,supraventricular ectopy,2,0,2,A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites.
EFO_0003777,heart disease,EFO_0009551,heart valve disease,2,2,5,A disease involving the cardial valve.
EFO_0003777,heart disease,EFO_1000985,intermediate coronary syndrome,2,2,12,"Angina pectoris (or equivalent type of ischemic discomfort) which has recently changed in frequency, duration, intensity, or occurs at rest."
EFO_0003777,heart disease,EFO_1001161,rheumatic heart disease,2,2,5,"An autoinflammatory condition following an infection with Group A Beta Hemolytic Streptococcus (GABHS), in which the heart is attacked by antibodies formed in reaction to a recent GABHS infection. Chief anatomic changes of the valve include leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords, all of which can result in valvular dysfunction."
EFO_0003777,heart disease,EFO_1001375,Myocardial Ischemia,3,3,84,"A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (coronary artery disease), to obstruction by a thrombus (coronary thrombosis), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction)."
EFO_0003777,heart disease,EFO_1001493,cardiac embolism,1,0,2,an embolism that is a result of an obstruction in a cardiac vessel due to a blood clot or other foreign matters
EFO_0003777,heart disease,EFO_1001771,cardiac edema,1,1,26,"Abnormal fluid retention by the body due to impaired cardiac function or heart failure. It is usually characterized by increase in venous and capillary pressure, and swollen legs when standing. It is different from the generalized edema caused by renal dysfunction (NEPHROTIC SYNDROME)."
EFO_0003777,heart disease,MONDO_0000591,intrinsic cardiomyopathy,2,2,9,A cardiomyopathy that is due to abnormalities in heart muscle cells.
EFO_0003777,heart disease,MONDO_0001302,hypertensive heart disease,2,2,3,Abnormal enlargement of the heart resulting from long-standing hypertension.
EFO_0003777,heart disease,MONDO_0004596,cor pulmonale,3,3,21,"Hypertrophy and dilation of the right ventricle of the heart that is caused by pulmonary hypertension. This condition is often associated with pulmonary parenchymal or vascular diseases, such as chronic obstructive pulmonary disease and pulmonary embolism."
EFO_0003777,heart disease,MONDO_0021661,coronary atherosclerosis,3,3,97,Atherosclerosis of the coronary vasculature.
EFO_0009270,heel bone mineral density,EFO_0009270,heel bone mineral density,12,6,3704,Quantification of the mineral density of the heel bone
EFO_0000537,hypertension,EFO_0000537,hypertension,25,9,934,"Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more."
EFO_0000537,hypertension,EFO_0001361,pulmonary arterial hypertension,1,0,3,"Pulmonary arterial hypertension (PAH) is a group of diseases characterized by elevated pulmonary arterial resistance leading to right heart failure. PAH is progressive and potentially fatal. PAH may be idiopathic and/ or familial, or induced by drug or toxin (drug-or toxin-induced PAH) or associated with other diseases like congenital heart disease, connective tissue disease, HIV, schistosomiasis, portal hypertension (PAH associated with other disease)."
EFO_0000537,hypertension,EFO_1002032,primary hypertension,3,2,82,Hypertension that presents without an identifiable cause.
EFO_0000768,idiopathic pulmonary fibrosis,EFO_0000768,idiopathic pulmonary fibrosis,1,0,13,Idiopathic pulmonary fibrosis (IPF) is a nonneoplastic pulmonary disease that is characterized by the formation of scar tissue within the lungs in the absence of any known cause.
EFO_0004995,lean body mass,EFO_0004995,lean body mass,24,12,7421,The weight of all organs and tissue in an individual less the weight of the individual's body fat.
EFO_0006792,Lewy body dementia,EFO_0006792,Lewy body dementia,3,0,3,"A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease."
EFO_0004529,lipid measurement,EFO_0004529,lipid measurement,50,0,97,A measure of circulating lipid
EFO_0004529,lipid measurement,EFO_0004530,triglyceride measurement,144,3,1975,"A triglyceride  measurement is a quantification of triglycerides in some body fluid, used as a biomarker for cardiovascular disease."
EFO_0004529,lipid measurement,EFO_0004611,low density lipoprotein cholesterol measurement,103,4,2309,The measurement of LDL cholesterol in blood used as a risk indicator for heart disease.
EFO_0004529,lipid measurement,EFO_0004612,high density lipoprotein cholesterol measurement,132,3,2366,The measurement of HDL cholesterol in blood used as a risk indicator for heart disease.
EFO_0004529,lipid measurement,EFO_0004622,sphingolipid measurement,13,0,22,Is a quantification of sphingolipids - molecules playing a role in signal transmission.
EFO_0004529,lipid measurement,EFO_0004639,phospholipid measurement,11,0,36,"Is a quantification of phospholipids, typically in blood used as a biomarker in diet studies."
EFO_0004529,lipid measurement,EFO_0005110,fatty acid measurement,20,0,34,The determination of the amount of fatty acids present in a sample.
EFO_0004529,lipid measurement,EFO_0005680,omega-6 polyunsaturated fatty acid measurement,9,0,15,The determination of the amount of omega-6 polyunsaturated fatty acids present in a sample.
EFO_0004529,lipid measurement,EFO_0006796,very long-chain saturated fatty acid measurement,3,0,7,The determination of the amount of very long-chain saturated fatty acids present in a sample. VLSFAs are fatty acids with 20 or more carbons.
EFO_0004529,lipid measurement,EFO_0006807,linoleic acid measurement,2,0,3,The determination of the amount of linoleic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0006808,arachidonic acid measurement,1,0,2,The determination of the amount of arachidonic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0006809,docosapentaenoic acid measurement,3,0,6,The determination of the amount of docosapentaenoic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0006810,oleic acid measurement,6,0,9,The determination of the amount of oleic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0006811,linolenic acid measurement,2,0,2,The determination of the amount of linolenic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0006821,trans fatty acid measurement,2,0,2,"The determination of the amount of trans fatty acids, a kind of unsaturated fatty acids, present in a sample."
EFO_0004529,lipid measurement,EFO_0006824,cis/trans-18:2 fatty acid measurement,1,0,1,"The determination of the amount of trans fatty acids with 18 carbons and 2 double bonds, with the first one in cis configuration and the 2nd one in trans configuration, present in a sample."
EFO_0004529,lipid measurement,EFO_0006826,trans/trans-18:2 fatty acid measurement,1,0,1,"The determination of the amount of trans fatty acids with 18 carbons and 2 double bonds, both of which are in trans configuration, present in a sample."
EFO_0004529,lipid measurement,EFO_0007630,glycerophospholipid measurement,35,0,38,"Is a quantification, typically in blood, of glycerophospholipids, a group of glycerol-based phospholipids"
EFO_0004529,lipid measurement,EFO_0007759,alpha-linolenic acid measurement,1,0,8,The determination of the amount of alpha-linolenic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0007760,eicosapentaenoic acid measurement,1,0,2,The determination of the amount of eicosapentaenoic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0007761,docosahexaenoic acid measurement,3,0,5,The determination of the amount of docosahexaenoic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0007804,LDL cholesterol change measurement,6,0,19,"quantification of the change in LDL cholesterol levels in an individual over time, eg over the course of several hours after a high-fat meal or following treatment with a cholesterol-lowering drug"
EFO_0004529,lipid measurement,EFO_0007805,HDL cholesterol change measurement,5,0,46,"quantification of the change in HDL cholesterol levels in an individual over time, eg over the course of several hours after a high-fat meal or following treatment with a cholesterol-lowering drug"
EFO_0004529,lipid measurement,EFO_0007929,triglyceride:HDL cholesterol ratio,1,0,2,quantification of the ratio of  triglyceride to HDL cholesterol in a sample
EFO_0004529,lipid measurement,EFO_0007930,LDL cholesterol:HDL cholesterol ratio,1,0,2,quantification of the ratio of LDL cholesterol to HDL cholesterol in a sample
EFO_0004529,lipid measurement,EFO_0007931,non-HDL cholesterol:HDL cholesterol ratio,1,0,1,quantification of the ratio of non-HDL cholesterol to HDL cholesterol in a sample
EFO_0004529,lipid measurement,EFO_0007973,palmitoleic acid measurement,1,0,4,The determination of the amount of palmitoleic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0007974,vaccenic acid measurement,2,0,4,The determination of the amount of vaccenic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0007975,gondoic acid measurement,2,0,3,The determination of the amount of gondoic acid present in a sample.
EFO_0004529,lipid measurement,EFO_0008317,very low density lipoprotein cholesterol measurement,29,0,51,quantification of the amount of very low density lipoprotein cholesterol in a sample
EFO_0004529,lipid measurement,EFO_0008350,alpha-linoleic acid measurement,1,0,1,quantification of the amount of alpha-linoleic acid in a sample
EFO_0004529,lipid measurement,EFO_0008359,eicosadienoic acid measurement,1,0,1,quantification of the amount of eicosadienoic acid in a sample
EFO_0004529,lipid measurement,EFO_0010118,sphingomyelin measurement,6,0,10,A quantification of sphingomyeline in a sample.
EFO_0004529,lipid measurement,EFO_0010222,ceramide measurement,7,0,9,A quantification of ceramides.
EFO_0004529,lipid measurement,EFO_0010224,lysophosphatidylcholine measurement,5,0,6,A quantification of lysophosphatidylcholines.
EFO_0004529,lipid measurement,EFO_0010225,lysophosphatidylethanolamine measurement,3,0,5,A quantification of lysophosphatidylethanolamines.
EFO_0004529,lipid measurement,EFO_0010226,phosphatidylcholine measurement,16,0,24,A quantification of phosphatidylcholines.
EFO_0004529,lipid measurement,EFO_0010227,phosphatidylcholine ether measurement,8,0,9,A quantification of phosphatidylcholine ethers.
EFO_0004529,lipid measurement,EFO_0010228,phosphatidylethanolamine measurement,3,0,4,A quantification of phosphatidylethanolamines.
EFO_0004529,lipid measurement,EFO_0010229,phosphatidylethanolamine ether measurement,3,0,4,A quantification of phosphatidylethanolamine ethers.
EFO_0004529,lipid measurement,EFO_0010230,phosphatidylinositol measurement,5,0,9,A quantification of phosphatidylinositols.
EFO_0004529,lipid measurement,EFO_0010340,cholesteryl ester 14:0 measurement,1,0,1,The quantification of cholesteryl ester 14:0 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010341,cholesteryl ester 16:0 measurement,1,0,3,The quantification of cholesteryl ester 16:0 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010346,cholesteryl ester 18:3 measurement,1,0,2,The quantification of cholesteryl ester 18:3 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010348,cholesteryl ester 20:4 measurement,1,0,2,The quantification of cholesteryl ester 20:4 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010349,cholesteryl ester 20:5 measurement,1,0,1,The quantification of cholesteryl ester 20:5 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010353,diacylglycerol 34:2 measurement,1,0,1,The quantification of diacylglycerol 34:2 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010354,diacylglycerol 36:1 measurement,1,0,2,The quantification of diacylglycerol 36:1 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010355,diacylglycerol 36:2 measurement,1,0,1,The quantification of diacylglycerol 36:2 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010362,lysophosphatidylcholine 20:3 measurement,1,0,1,The quantification of lysophosphatidylcholine 20:3 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010363,lysophosphatidylcholine 20:4 measurement,1,0,1,The quantification of lysophosphatidylcholine 20:4 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010364,lysophosphatidylcholine 20:5 measurement,1,0,1,The quantification of lysophosphatidylcholine 20:5 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010365,lysophosphatidylcholine 22:6 measurement,1,0,1,The quantification of lysophosphatidylcholine 22:6 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010366,lysophosphatidylethanolamine 16:0 measurement,1,0,2,The quantification of lysophosphatidylethanolamine 16:0 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010367,lysophosphatidylethanolamine 18:0 measurement,1,0,1,The quantification of lysophosphatidylethanolamine 18:0 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010369,lysophosphatidylethanolamine 18:2 measurement,1,0,1,The quantification of lysophosphatidylethanolamine 18:2 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010370,lysophosphatidylethanolamine 20:4 measurement,1,0,2,The quantification of lysophosphatidylethanolamine 20:4 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010373,phosphatidylcholine 32:1 measurement,1,0,1,The quantification of phosphatidylcholine 32:1 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010374,phosphatidylcholine 32:2 measurement,1,0,1,The quantification of phosphatidylcholine 32:2 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010376,phosphatidylcholine 34:2 measurement,1,0,1,The quantification of phosphatidylcholine 34:2 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010377,phosphatidylcholine 34:3 measurement,1,0,2,The quantification of phosphatidylcholine 34:3 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010382,phosphatidylcholine 36:4 measurement,1,0,2,The quantification of phosphatidylcholine 36:4 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010386,phosphatidylcholine 38:4 measurement,1,0,2,The quantification of phosphatidylcholine 38:4 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010387,phosphatidylcholine 38:5 measurement,1,0,2,The quantification of phosphatidylcholine 38:5 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010389,phosphatidylcholine 40:6 measurement,1,0,1,The quantification of phosphatidylcholine 40:6 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010390,sphingomyelin 14:0 measurement,1,0,3,The quantification of sphingomyelin 14:0 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010398,sphingomyelin 24:1 measurement,1,0,2,The quantification of sphingomyelin 24:1 levels in a sample.
EFO_0004529,lipid measurement,EFO_0010405,triacylglycerol 48:2 measurement,1,0,1,"The quantification of triacylglycerol 48:2 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010406,triacylglycerol 48:3 measurement,1,0,1,"The quantification of triacylglycerol 48:3 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010410,triacylglycerol 50:3 measurement,1,0,1,"The quantification of triacylglycerol 50:3 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010411,triacylglycerol 50:4 measurement,1,0,1,"The quantification of triacylglycerol 50:4 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010414,triacylglycerol 52:2 measurement,1,0,1,"The quantification of triacylglycerol 52:2 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010416,triacylglycerol 52:4 measurement,1,0,1,"The quantification of triacylglycerol 52:4 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010417,triacylglycerol 52:5 measurement,1,0,1,"The quantification of triacylglycerol 52:5 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010420,triacylglycerol 54:2 measurement,1,0,1,"The quantification of triacylglycerol 54:2 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010421,triacylglycerol 54:3 measurement,1,0,1,"The quantification of triacylglycerol 54:3 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010422,triacylglycerol 54:4 measurement,1,0,1,"The quantification of triacylglycerol 54:4 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010423,triacylglycerol 54:5 measurement,1,0,2,"The quantification of triacylglycerol 54:5 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010428,triacylglycerol 56:10 measurement,1,0,1,"The quantification of triacylglycerol 56:10 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010430,triacylglycerol 56:3 measurement,1,0,1,"The quantification of triacylglycerol 56:3 levels in some body fluid, used as a biomarker for disease."
EFO_0004529,lipid measurement,EFO_0010437,triacylglycerol 58:10 measurement,2,0,2,"The quantification of triacylglycerol 58:10 levels in some body fluid, used as a biomarker for disease."
EFO_0004300,longevity,EFO_0004300,longevity,10,0,47,The  length of time of an organism's life.
EFO_0004300,longevity,EFO_0007796,parental longevity,15,8,113,"length of an individual's parents' life, either taken individually (paternal or maternal longevity) or in combination and sometimes used as an indicator of an individual longevity"
EFO_0000195,metabolic syndrome,EFO_0000195,metabolic syndrome,14,0,126,"A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)"
HP_0002180,Neurodegeneration,HP_0002180,Neurodegeneration,,,,Progressive loss of neural cells and tissue.
EFO_0001073,obesity,EFO_0001073,obesity,21,8,137,A disorder involving an excessive amount of body fat.
EFO_0002506,osteoarthritis,EFO_0002506,osteoarthritis,15,8,101,"A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity."
EFO_0002506,osteoarthritis,EFO_0004616,"osteoarthritis, knee",11,8,85,Knee osteoarthritis is a degenerative disease of the knee joint
EFO_0002506,osteoarthritis,EFO_1000786,"osteoarthritis, hip",15,9,112,"Osteoarthritis of the hip is also very common and can affect either one or both hips.
You’re most likely to feel pain deep at the front of your groin, but also at the side and front of your thigh, in your buttock or down to your knee (this is called radiated pain).
If you have severe hip osteoarthritis, you may find your affected leg seems a little shorter than the other because of the bone on either side of your joint being crunched up."
EFO_0002506,osteoarthritis,EFO_1000787,"osteoarthritis, spine",2,2,3,"Changes that affect the bones of your spine and the discs between the bones are often called spondylosis, but they’re very similar to the changes caused by osteoarthritis in other joints. X-rays show that spondylosis is extremely common, but it’s not the most common cause of back pain or neck pain and often doesn’t cause any problems at all."
EFO_0002506,osteoarthritis,EFO_1000789,"osteoarthritis, hand",1,0,1,"Osteoarthritis of the hands usually happens as part of nodal osteoarthritis (a form of osteoarthritis that runs in families). This mainly affects women and often starts in your 40s or 50s, around the menopause (the time when menstruation ends and it’s no longer possible to have children)."
EFO_0003882,osteoporosis,EFO_0003882,osteoporosis,8,4,20,"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss)."
EFO_0002508,Parkinson's disease,EFO_0002508,Parkinson's disease,21,2,244,"A neurodegenerative disease that results_from degeneration of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions."
EFO_0000685,rheumatoid arthritis,EFO_0000685,rheumatoid arthritis,42,9,521,"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated."
EFO_0000685,rheumatoid arthritis,EFO_0003898,ankylosing spondylitis,10,0,237,An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.
EFO_0000685,rheumatoid arthritis,EFO_0009459,ACPA-positive rheumatoid arthritis,2,2,18,A subtype of rheumatoid arthritis defined by the presence of autoantibodies that are directed against citrullinated peptides and proteins.
EFO_1000653,sarcopenia,EFO_1000653,sarcopenia,,,,Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
EFO_0000712,stroke,EFO_0000712,stroke,24,9,111,"A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)"
EFO_0000712,stroke,EFO_0005524,large artery stroke,9,1,33,stroke caused by the blockage of blood flow in one of the large arteries feeding the brain
EFO_0000712,stroke,EFO_1001504,small vessel stroke,4,0,4,stroke caused by the blockage of blood flow in one of the small blood vessels in the brain
EFO_0000712,stroke,EFO_1001976,cardioembolic stroke,7,1,20,stroke caused by the blockage of blood flow in a brain vessel through a clot or other foreign matters pumped from the heart to the brain
EFO_0001360,type II diabetes mellitus,EFO_0001360,type II diabetes mellitus,90,16,3062,A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.